ESMO Congress 2023 Virtual Platform

(38)

Department of oncology - Esmo Congress TV

(6:29)

ESMO 2022 Highlights

(1:)

ESMO Congress 2024 GU Round-Up: Prostate Cancer

(6:30)

ESMO Congress 2021: Prof. Solange Peters on what is special about the congress

(56)

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLC

(7:)

Expert Commentary: Developmental therapeutics at ESMO Congress 2021

(10:19)

ESMO Congress 2019 Daily Reporter - Editor's Picks: Prostate cancer

(27)

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC

(5:18)

ESMO 2024: Highlights and analysis

(24:35)

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2

(4:17)

Highlights on datopotamab deruxtecan in advanced NSCLC: The TROPION-Lung01 study

(3:9)

Highlights on sotorasib plus panitumumab in KRAS G12C-mutated mCRC: The CodeBreak 300 study

(4:9)

ESMO 2023 Highlights

(3:12)

How to select treatment for HER2+ breast cancer patients with brain metastasis?

(6:47)

Highlights on pembro + CRT in high-risk locally advanced cervical cancer: The KEYNOTE-A18 study

(3:15)

Highlights on adjuvant alectinib in early ALK positive NSCLC: The ALINA study

(2:51)

ESMO 2024 Kidney Preview: TiNivo-2, SUNNIFORECAST, CheckMate 9ER, and More

(7:3)

ESMO Congress 2023 Patient Advocacy Track Testimonial with Natacha Bolanos

(1:51)

Expert Commentary: Immunotherapeutics at ESMO Congress 2021

(9:16)

ESMO Congress 2021: Rosa Giuliani - Patient Advocacy Track

(3:30)

ESMO Congress Round-Up With Dr. Evan Yu: Part 1

(4:31)

ESMO Congress 2023 Patient Advocacy Track Testimonial with André Deschamps

(1:14)

ESMO 2024 Conference Wrap-Up with Rebecca Dent, MD, FRCP, Scientific Chair

(6:24)

Follow the ESMO Congress 2019 on the new digital Daily Reporter

(30)

ESMO 2019 Daily Reporter - Editor's Picks: Lung cancer

(36)

ESMO Gynaecological Cancers Congress 2024 Members of the Scientific Committee invite you to register

(1:23)

ESMO Congress 2023 Patient Advocacy Track Testimonial with Barbara Moss

(2:15)